
MeMed Stock
MeMed Diagnostics is a personalized diagnostics company, focused on preventing antibiotics misuse.
Sign up today and learn more about MeMed Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About MeMed Stock
MeMed Diagnostics is a personalized diagnostics company founded in 2009. They are here to improve patient care, empower physicians, and lower health-care costs through rapid and actionable diagnostics for infectious diseases. Their main focus is preventing antibiotics misuse. Antibiotics are the most prescribed class of drugs worldwide with a global market of 25-30 billion $US. Up to 70% of antibiotics are estimated to be prescribed inappropriately, making them the most misused drug class in the world. Antibiotics misuse leads to ineffective treatment, emergence of resistant strains of bacteria, and is estimated to cost healthcare systems worldwide tens of billions of dollars annually. Their platform, the ImmunoDx™, leverages the world’s most accurate diagnostic system for differentiating bacteria from viruses, crafted by nature, the body’s immune system. ImmunoDx™ combines proprietary biomarkers, algorithms, and clinical know-how to identify the source of infection (virus vs bacteria, bacterial spectrum), by decoding the immune system`s differential response to different pathogens. This unique approach enables ImmunoDx™ to address some of the major challenges facing currently available diagnostics for infectious diseases.
Funding History
December 2015 | $2.9M |
---|---|
February 2018 | $4.1M |
September 2018 | $70.0M |
November 2019 | $2.5M |
January 2022 | $93.0M |
Management
VP R&D
Oren Zarchin
VP of Human Resources
Hila Hershkovitz
VP Finance
Kfir Emmer
Investor
Lyon Wong
COO
Idan Danenberg
Investor
Kent Ho
Chief Business Development Officer
Frederic Sweeney
VP Commercial Strategic Markets
Adee Mor
VP Commercial and Corporate Development
Ofer Halbreich
Co-founder and CEO
Eran Eden
Co-founder, CTO, Chairman
Kfir Oved
VP of Scientific Affairs
Tanya Gottlieb
Director of Regulatory Affairs and Quality Assurance
Efrat Hartog-David
Press
jpost - Nov, 17 2019
Israeli company wins €2.5M to combat drug resistancebioportfolio - Nov, 14 2019
MeMed Wins €2.5M Award from European Innovation Councilnocamels - Apr, 23 2017
Report: Microsoft Buying Israel’s Cloudyn for $50-70Mgenengnews - Apr, 19 2017
MeMed Wins $9.2M DTRA Contract for PoC IVD to Reduce Antibiotic Misuseprnewswire - Dec, 25 2016
Lancet Infectious Diseases Publishes Independent Double-Blind Study Validating MeMed's Immunoxpert™ Blood Test's Ability to Accurately Distinguish Between Bacterial and Viral Infections in Childrenbusinesswire - Mar, 7 2016
IATI-Biomed, Israel’s Leading Life Science Conference, Celebrates its 15th Anniversarynocamels - Jan, 9 2016
Meet The Top Israeli Startups Revolutionizing Everyday Healthcarebusinesswire - Sep, 29 2015
MeMed awarded €3M from the European Commission in high profile business competitionEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase